Yesterday, a reporter learned that the results of Phase III clinical trials for the hand, foot, and mouth disease (HFMD) vaccine have shown it to be 95% effective in preventing the illness. This breakthrough could significantly reduce the impact of HFMD on children and their families, offering long-awaited relief from this widespread childhood disease. The Phase III clinical trial for the EV71 vaccine officially began last year on January 6th, with over 10,000 infants receiving the vaccination. A full year of follow-up data showed strong epidemiological protection. The results indicated that three doses of the EV71 vaccine provide good immunity for children aged 6 months to 5 years, with high safety standards. HFMD is a common viral infection among young children, typically peaking during summer. Due to frequent outbreaks in kindergartens, the vaccine requires two doses. It is expected to receive approval for market release by the second half of this year. However, it remains unclear whether the vaccine will be included in the national immunization program. Once available, its price will likely be similar to that of Class II vaccines. Although HFMD can be prevented and treated, there has been no global vaccine specifically targeting EV71 until now. Chinese experts emphasize that this vaccine represents a major step forward. Dr. Zeng Guang, a senior epidemiologist at the Chinese Center for Disease Control and Prevention, warned that without an effective treatment or widely available vaccine, HFMD is expected to remain a significant public health challenge in the coming period. The EV71 vaccine developed by Beijing Kexing Bio-products Co., Ltd. is produced using African monkey kidney cells, with the virus cultured, harvested, inactivated, purified, and adsorbed onto aluminum. The vaccine has already passed verification by the China Food and Drug Testing Institute, and Phase III clinical trials are expected to begin soon. Yin Weidong, head of vaccine development, explained that earlier trials focused on safety and efficacy, while the current Phase III trial emphasizes the vaccine’s protective effect and long-term immunity. As the world watches closely, this new vaccine offers hope for better control of HFMD, especially in regions where outbreaks are most common. With more research and real-world data, the future looks brighter for protecting children from this preventable disease. Diverse product selection: PVC floor mat manufacturers in China usually offer a wide selection of products, including different designs, sizes and functions. This diversity allows buyers in Europe and the United States to choose appropriate products according to market needs and consumer preferences. Swimming pool mats,Non Slip Bath Mat,Non Slip Mat,Pool Mat,Under Pool Mat Jiangyin Yining E-Commerce Co., Ltd , https://www.pvcmatyining.com
High quality standards: With the continuous development of China's manufacturing industry, many manufacturers have strengthened the control of product quality. While meeting international standards, China's Pvc floor mats also provide certain customization and upgrade options to meet the demand for high-quality products in Europe and the United States.